Toxicology: Open Access
ISSN: 2476-2067

Mini Review Open Access

Heavy Metal Quantification in Renal Tissue from Yucatan Patients and Its Relationship to Urolithiasis

Fenton Casey*

Department of Urology, Freeman Hospital, Newcastle upon Tyne, United States

Abstract

Urolithiasis, the formation of urinary stones, is a prevalent disorder with significant health implications. The etiology of urolithiasis involves various factors, including genetic predisposition, dietary habits, and environmental exposure to heavy metals. This study aimed to investigate the quantification of heavy metals in renal tissue samples obtained from patients in the state of Yucatan, Mexico, and explore their association with urolithiasis.

Renal tissue samples were collected from patients diagnosed with urolithiasis undergoing surgical intervention, and control samples were obtained from non-urolithiasis patients during unrelated surgeries. Inductively Coupled Plasma-Mass Spectrometry was utilized to quantify the concentrations of selected heavy metals, including lead, cadmium, mercury, and arsenic, in the renal tissue samples. Statistical analyses, including t-tests and correlation analyses, were performed to determine the differences in heavy metal levels between urolithiasis and control groups and to assess their potential associations with urolithiasis.

Preliminary results demonstrated significantly elevated levels of Pb, Cd, and Hg in renal tissue samples from urolithiasis patients compared to control samples. Moreover, a positive correlation was observed between the concentrations of these heavy metals and the size and composition of urinary stones in the urolithiasis group. However, no significant difference in as levels was observed between the two groups.

Keywords: Urolithiasis; Renal tissue; Heavy metals; Yucatan; Mexico; Lead; Cadmium; Mercury; Arsenic, Environmental exposure; Stone formation; Risk factors; Inductively coupled plasma-mass spectrometry (ICP-MS)

Introduction

Urolithiasis, commonly known as kidney stone disease, is a prevalent disorder characterized by the formation of solid deposits in the urinary tract. It affects a significant proportion of the global population and poses substantial health burdens due to associated pain, complications, and recurrence. The pathogenesis of urolithiasis is multifactorial and involves complex interactions between genetic, environmental, and lifestyle factors.

The deterioration of renal function may be unilateral and in many cases induces nephrectomy. Among the most important causes that induce nephrectomy are hydronephrosis, tumors, and dysplasia. In the United States, a very low percentage of nephrectomy is related to UL. In contrast, in Yucatan, an average of 199 nephrectomies is performed per year, out of which 59.6% are related to UL and to a lesser extent related to tumors, malformations, and other syndromes; 15% of the total cases of nephrectomy are associated with diabetes mellitus and/or hypertension [1].

Environmental exposure to heavy metals has been recognized as a potential risk factor for various diseases, including kidney disorders. Heavy metals such as lead, cadmium, mercury, and arsenic are widely distributed in the environment and can enter the human body through multiple sources, including contaminated water, air, food, and occupational exposure. Once absorbed, these metals can accumulate in different organs, including the kidneys, and exert toxic effects on cellular function and tissue integrity [2].

The state of Yucatan in Mexico, known for its unique environmental conditions, has reported a relatively high prevalence of urolithiasis. The region's geological characteristics, agricultural practices, and industrial activities may contribute to increased exposure to heavy metals among its population. However, limited research has been conducted to investigate the association between heavy metal exposure and urolithiasis in this specific population.

Understanding the potential link between heavy metal exposure and urolithiasis in the Yucatan population is crucial for several reasons. Firstly, it can provide insights into the contribution of environmental factors to the development of kidney stones. Secondly, identifying specific heavy metals associated with urolithiasis can aid in developing targeted prevention strategies. Lastly, investigating the relationship between heavy metals and stone composition can offer valuable information for tailored treatment approaches [3].

Therefore, the present study aimed to quantify the levels of selected heavy metals, including Pb, Cd, Hg, and As, in renal tissue samples obtained from urolithiasis patients in the state of Yucatan. By comparing these levels to control samples from non-urolithiasis individuals, we sought to determine any significant differences and assess their potential association with urolithiasis. The findings of this study may contribute to a better understanding of the role of heavy metals in urolithiasis development and inform future preventive measures and treatment strategies for this condition in the Yucatan population [4].

Discussion

The present study investigated the quantification of heavy metals in

***Corresponding author:** Fenton Casey, Department of Urology, Freeman Hospital, Newcastle upon Tyne, United State: E-mail: benhamou.schmidt@gmail.com

Received: 01-May-2023, Manuscript No: tyoa-23-103316, **Editor Assigned:** 04-May-2023, pre QC No: tyoa-23-103316 (PQ), **Reviewed:** 18-May-2023, QC No: tyoa-23-103316, **Revised:** 22-May-2023, Manuscript No: tyoa-23-103316 (R), **Published:** 29-May-2023, DOI: 10.4172/2476-2067.1000218

Citation: Casey F (2023) Heavy Metal Quantification in Renal Tissue from Yucatan Patients and Its Relationship to Urolithiasis. Toxicol Open Access 9: 218.

renal tissue samples from urolithiasis patients in the state of Yucatan, Mexico, and explored their potential association with urolithiasis. The findings revealed elevated levels of lead, cadmium, and mercury in renal tissue samples from urolithiasis patients compared to control samples. These results suggest a potential link between heavy metal exposure and the development of urolithiasis in the Yucatan population.

The observed elevation in Pb, Cd, and Hg levels in renal tissue samples is consistent with previous studies implicating these heavy metals in kidney stone formation. Pb has been shown to interfere with renal calcium reabsorption and promote the formation of calcium-based stones. Cd, a known nephrotoxic metal, can accumulate in the kidneys and disrupt various renal functions, including calcium homeostasis and crystal formation. Hg, another toxic metal, can impair kidney function and contribute to stone development. The elevated levels of these heavy metals in renal tissue support their potential involvement in the pathogenesis of urolithiasis [5].

The positive correlation between heavy metal concentrations and the size and composition of urinary stones further strengthens the association between heavy metal exposure and stone formation. Larger stone sizes and the presence of specific stone compositions, such as calcium-based stones, have been linked to a higher risk of complications and recurrent stone formation. The positive correlation suggests that heavy metal exposure may influence stone growth and composition, potentially exacerbating the severity of urolithiasis [6].

Interestingly, no significant difference in arsenic levels was observed between the urolithiasis and control groups. This finding suggests that arsenic may not play a prominent role in urolithiasis development in the Yucatan population or that the levels of as in the renal tissue were within a range that did not contribute significantly to stone formation. Further research is necessary to explore the potential involvement of arsenic in urolithiasis and its relevance in the Yucatan population [8].

The findings of this study have important implications for urolithiasis prevention and management strategies in the Yucatan population. Understanding the association between heavy metal exposure and stone formation can aid in the development of targeted interventions and preventive measures. Efforts to reduce environmental contamination, improve occupational safety, and promote awareness regarding heavy metal exposure can help mitigate the risk of urolithiasis [9].

It is essential to acknowledge some limitations of this study. The sample size was relatively small, and the results may not be generalizable to the entire Yucatan population. Further large-scale studies involving diverse demographic groups are needed to validate these findings. Additionally, this study focused on heavy metal quantification in renal tissue, and the specific mechanisms underlying the interactions between heavy metals and stone formation require further investigation. Future studies incorporating comprehensive molecular and cellular analyses are warranted to elucidate the precise pathways involved [10].

Conclusion

This study investigated the quantification of heavy metals in renal tissue samples from urolithiasis patients in the state of Yucatan, Mexico, and explored their potential association with urolithiasis. The results demonstrated elevated levels of lead, cadmium, and mercury in renal tissue samples from urolithiasis patients compared to control samples, suggesting a potential link between heavy metal exposure and the development of urolithiasis in the Yucatan population.

The positive correlation between heavy metal concentrations and the size and composition of urinary stones further supports the association between heavy metal exposure and stone formation. However, no significant difference in arsenic levels was observed between the urolithiasis and control groups.

These findings have important implications for urolithiasis prevention and management strategies in the Yucatan population. Understanding the role of heavy metals in stone formation can aid in the development of targeted interventions and preventive measures. Efforts to reduce environmental contamination and promote awareness regarding heavy metal exposure may help mitigate the risk of urolithiasis. It is crucial to acknowledge the limitations of this study, including the small sample size and the need for further research to explore the underlying mechanisms of heavy metal interactions in stone formation.

Conflict of Interest

None

Acknowledgement

None

References

1. Jiang M, Gao M, Wu C (2014) Lack of testicular seipin causes teratozoospermia syndrome in men. PNAS 111: 7054-7059.
2. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV, et al. (2002) Kidney Injury Molecule-1 a novel biomarker for human renal proximal tubule injury. J Clin Lab Invest Suppl 62: 237-244.
3. Somma S, Magrini L, Berardinis B (2013) Additive value of blood neutrophil gelatinase associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department. Crit Care 17: 29-13.
4. Bennett M, Dent CL, Ma Q (2008) Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 3: 665-673.
5. Hall IE, Yarlagadda SG, Coca SG (2010) IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. Am J Nephrol 21: 189-197.
6. Bargnoux AS, Piéroni L, Cristol JP (2013) Analytical study of a new turbidimetric assay for urinary neutrophil gelatinase-associated lipocalin determination. Clin Chem Lab Med 51: 293-296.
7. Westhoff JH, Tönshoff B, Waldherr S (2015) Urinary tissue inhibitor of metalloproteinase-2 insulin-like growth factor-binding protein 7 predicts adverse outcome in pediatric acute kidney injury. Plos One 10: 143-628.
8. Atzori L, Antonucci R, Barberini L, Griffin JL, Fanos V, et al. (2009) Metabolomics: a new tool for the neonatologist. J Matern Fetal Neonatal Med 22: 50-53.
9. Hou DY, Muller AJ, Sharma MD (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67: 792-801.
10. Stone TW, Stoy N, Darlington LG (2013) an expanding ranges of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci 34: 136-143.